Electrophysiology & Arrhythmia | May 2020

The findings were originally scheduled to be presented at the Heart Rhythm Society’s 2020 Heart Rhythm Scientific Sessions.

The potential use of hydroxychloroquine to treat COVID-19 has been one of the biggest stories of the current pandemic.

Researchers studied data from 1,051 patients who received resterilized pacemakers and defibrillators, sharing their findings in the New England Journal of Medicine.

In addition to these latest findings, a NIH-backed panel is now specifically recommending against the combination of hydroxychloroquine and azithromycin for treating COVID-19 patients.

Treating COVID-19 patients with hydroxychloroquine, alone or in combination with azithromycin, is associated with an increased risk of QTc prolongation, according to two new studies published in JAMA Cardiology.

A new wearable necklace can be used to detect atrial fibrillation (AFib), according to new findings published through the European Society of Cardiology’s EHRA Essentials 4 You platform.

Coala Life, a healthcare technology company based out of Sweden, has announced that physicians will now be able to use the company’s Coala Heart Monitor to conduct virtual heart and lung examinations.

Cardiologs has announced the beginning of a new clinical trial that will involve monitoring the cardiac health of COVID-19 patients being treated with hydroxychloroquine and azithromycin.

Novartis is launching a new clinical trial to assess the effectiveness of treating hospitalized COVID-19 patients with hydroxychloroquine.